When recurring abdominal pain and diarrhea strike, most people first assume they are dealing with a standard bout of gastroenteritis or irritable bowel syndrome. However, if these symptoms persist for several weeks, or are accompanied by bloody stools, unexplained weight loss, or perianal pain, the possibility of inflammatory bowel disease (IBD) must be considered. Characterized by chronic, relapsing inflammation of the digestive tract, IBD primarily manifests as two distinct clinical conditions: Crohn’s disease and ulcerative colitis.
May 19 marks World IBD Day, an international initiative established to elevate public understanding of these complex conditions, share the daily challenges faced by patients, and promote appropriate therapeutic strategies. Although IBD remains a challenging, incurable disease requiring lifelong management, early diagnosis and continuous medical intervention can successfully suppress symptoms and allow patients to maintain a high quality of life.
The patient population in South Korea is climbing steadily. As of 2024, approximately 35,000 individuals in the country are living with Crohn’s disease, while roughly 62,000 are diagnosed with ulcerative colitis. Once considered predominantly Western ailments, these diseases have rapidly expanded their footprint in South Korea due to shifting dietary patterns and environmental modifications, alongside improved diagnostic capabilities. Alarmingly, a substantial portion of these cases are diagnosed in young adults actively engaged in education, career-building, and social activities, severely impacting their overall quality of life.
While Crohn’s disease and ulcerative colitis are both classified as chronic inflammatory bowel diseases, they affect different regions of the digestive tract and exhibit unique pathological patterns. Crohn’s disease can trigger inflammation anywhere from the mouth to the anus, often penetrating deep into the transmural layers of the intestinal wall, with common symptoms including abdominal pain, severe diarrhea, weight loss, fever, and perianal abscesses or fistulas. In contrast, ulcerative colitis is typically confined to the mucosa of the colon and rectum, primarily causing frequent bowel movements, abdominal cramps, and stools mixed with blood and mucus.
A primary challenge in managing IBD is that a reduction in physical symptoms does not necessarily mean the internal inflammation has completely cleared. When diarrhea or abdominal pain subsides, patients frequently assume their disease is under control, even though active inflammation may still linger in the intestinal mucosa. Leaving this underlying inflammation unchecked sharply increases the risk of a clinical relapse and elevates the likelihood of severe complications, such as intestinal strictures or fistulas, which often lead to hospitalization and surgical intervention.
Consequently, modern therapeutic objectives for IBD have expanded beyond basic symptom relief toward long-term disease modification. The core focus is to eradicate intestinal inflammation and sustain "remission"—a completely symptom-free state—for as long as possible to maximize patient well-being. While historical approaches prioritized the resolution of clinical symptoms like bloody stools and abdominal pain, contemporary gastroenterology places immense emphasis on "endoscopic remission," which denotes the structural healing of mucosal tissue observed via endoscopy. Moving forward, clinicians are increasingly targeting "deep remission," a state that mandates the resolution of cellular inflammation verified through microscopic tissue biopsies.
Achieving endoscopic remission serves as a critical clinical indicator linked to superior long-term outcomes, including a lower probability of future disease acceleration and a reduced need for surgical resections. Because internal disease activity cannot be reliably measured by subjective physical sensations alone, patients must work closely with their specialists to verify their inflammatory status using routine blood panels, fecal biomarker tests, and endoscopic evaluations.
However, a notable divergence in perception persists between patients and their physicians regarding what constitutes successful treatment. Clinical survey data reveals that while patients tend to evaluate remission based almost exclusively on subjective symptom relief, costly objective data reveals that roughly 65% of healthcare professionals define remission using objective diagnostic metrics and endoscopic findings. Furthermore, more than 60% of surveyed patients reported that they had never heard of the concept of mucosal healing or endoscopic remission. This disparity underscores a critical need for transparent, thorough communication regarding long-term therapeutic milestones between patients and their medical teams.
"Because it is often impossible to confirm that inflammatory bowel disease is truly controlled based on symptom improvement alone, targeting deeper levels of disease management, such as endoscopic remission, has become paramount," said Jung Sung-ae, president of the Korean Association for the Study of Intestinal Diseases and a professor in the Division of Gastroenterology at Ewha Womans University Seoul Hospital. Professor Jung emphasized that "since patients and clinicians frequently harbor differing understandings of what 'remission' means, it is vital to co-create a personalized therapeutic strategy that accounts for the patient's individual lifestyle through open communication and shared decision-making."
Effectively managing IBD requires a combination of long-term pharmacological therapy and deliberate lifestyle modifications. Depending on the disease phenotype and individual severity, drug regimens may utilize anti-inflammatory agents, immunomodulators, biologics, or advanced targeted small molecules. Patients who independently taper or halt their medications upon feeling better face an immediate, heightened risk of relapse, making continuous consultation with a specialist non-negotiable. Lifestyle vigilance is equally imperative, as psychological stress, sleep deprivation, smoking, and erratic eating habits are well-established triggers for acute disease flare-ups.
In observance of World IBD Day, global pharmaceutical companies are executing public awareness initiatives to bridge these communication gaps. Janssen Korea is currently spearheading its "Inside Dream" campaign, an educational movement designed to help patients manage their pathology and communicate more effectively with clinical professionals. As part of this campaign, the company is distributing a comprehensive communication guide featuring detailed disease explanations, symptom-tracking frameworks, and collaborative treatment-goal architectures to actively support shared decision-making between IBD patients and their healthcare providers.
